logo

BioMed Research International

BioMed Research International / 2012 / Article / Tab 3

Review Article

Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug

Table 3

Drug interactions of artemisinins.
Drug combinationCancer/cell lineEffectRefs
DHA + TemozolomideRat C6 glioma cellsIncreased apoptosis, ROS
Induced necrosis		[107]
DHA + CyclophosphamideLewis lung carcinomaIncreased apoptosis, decreased VEGF receptor KDR/flk-1
Apoptosis		[84]
DHA + CisplatinHuman non-small cell lung cancer (A549)Decreased metastasis[84]
DHA + GemcitabinePancreas (Panc-1)
Inhibition of proliferation, decreased cyclin D1
Increased apoptosis, increased Bax/Bcl2 ratio, activation of caspase 3		[94]
Hepatoma (cell panel)Increased growth inhibition by 45%[67]
DHA + Butyric acidHuman lymphoblastoid leukemia (Molt-4)Synergistic. Depletion of cancer cells[110]
DHA + RadiationGlioma cells
U373MG		Increased cytotoxicity
Inhibition of radiation-induced GST		[53]
DHA + CarboplatinOvarian cancer cells (A2780, OVCAR-3)Increased growth inhibition through death receptor and mitochondrial mediated pathways[77]
DHA + TRAILProstate cancer (DU145, PC-3, LNCaP)Increased apoptosis extrinsic and intrinsic pathways[100]
ART/DHA + Doxorubicin + PirarubicinLeukemia (K562/adr)
Small cell lung cancer (GLC4/adr)		Synergistic[4]
ART + LenalidomideLung (A549) and breast (MCF-7)Decreased IC50 by 48%[111]
ART + OxiplatinColon (HT 1116)Additive. Sensitising effect [111]
ART + GemcitabineBreast (MCF-7)Additive
Lung (A549)Additive
ATM + Oxiplatin
ATM + Thalidomide
ATM + Gemcitabine
Colon (HCTl16, SW480)
Breast (MCF-7)		All additive[63]
ARS + Hyperbaric oxygen (HBO2)Molt-4 human leukemia22% decrease in growth[112]
ARS + DoxorubicinColon cancer(HT29)Predicted as antagonic, mediated by activation of NF-κB/overexpression of Pgp[59]
ARS + OxiplatinColon (HCTl16, SW480)Antagonism [63]
ARS + ThalidomideAdditive
ARS + GemcitabineBreast (MCF-7)Antagonism
Abbreviations: HBO2: hyperbaric oxygen.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.